DRREDDY.NS - Dr. Reddy's Laboratories Limited
| Previous Close | 2,536.05 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 2,512.70 - 2,587.45 |
| 52 Week Range | 1,872.95 - 2,964.00 |
| Volume | 501,186 |
| Avg. Volume | 639,330 |
| Market Cap | 427.974B |
| Beta (3Y Monthly) | 0.09 |
| PE Ratio (TTM) | 22.80 |
| EPS (TTM) | 113.09 |
| Earnings Date | May 10, 2018 - May 14, 2018 |
| Forward Dividend & Yield | 20.00 (0.79%) |
| Ex-Dividend Date | 2019-07-15 |
| 1y Target Est | 2,587.45 |
- Business Wire•yesterday
Dr. Reddy's Laboratories Announces the Launch of Tobramycin Inhalation Solution, USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI® Inhalation Solution, approved by the U.S.
- Simply Wall St.•2 days ago
Dr. Reddy's Laboratories Limited (NSE:DRREDDY): What We Can Expect From This Growth Stock
Looking at Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) earnings update on 31 March 2019, it seems that analyst...
- Simply Wall St.•2 days ago
Dr. Reddy's Laboratories Limited (NSE:DRREDDY): What Does The Future Look Like?
As Dr. Reddy's Laboratories Limited (NSE:DRREDDY) released its earnings announcement on 31 March 2019, it seems that...
- Business Wire•4 days ago
Dr. Reddy's Laboratories Announces the Launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules, a therapeutic equivalent generic version of Vitamin K1 Injectable Emulsion USP, 10 mg/ml, approved by the U.S.
- Business Wire•12 days ago
Dr. Reddy’s Laboratories Announces Entering into a Definitive Agreement to Sell Its Neurology Branded Products to Upsher-Smith Laboratories, LLC
Dr. Reddy’s Laboratories Limited announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC , pursuant to which Dr.
- Business Wire•16 days ago
Dr. Reddy's Laboratories Limited Through Its Wholly Owned Subsidiary, Dr. Reddy’s Laboratories SA, Announces Positive Topline Results from Phase 2b Study of PPC-06 in Patients with Moderate to Severe Plaque Psoriasis
Dr. Reddy’s Laboratories Ltd. announced positive topline results from its Phase 2b study of PPC-06 in patients with moderate to severe plaque psoriasis.
- Business Wire•22 days ago
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
Dr. Reddy’s Laboratories Limited today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended March 31, 2019 was filed with the United States Securities and Exchange Commission on June 3, 2019.
- Business Wire•23 days ago
Dr. Reddy's Laboratories Announces the Re-Launch of Zenatane® (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the re-launch of Zenatane® , 10 mg, 20 mg, 30 mg and 40 mg, a therapeutic equivalent generic version of Accutane®, approved by the U.S.
- Business Wire•last month
Dr. Reddy’s Q4 & FY19 Financial Results
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2019 under International Financial Reporting Standards .
- Simply Wall St.•last month
Did You Miss Dr. Reddy's Laboratories's (NSE:DRREDDY) 40% Share Price Gain?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Business Wire•last month
Dr. Reddy's Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Daptomycin for Injection, 500mg/vial single-dose vial, a therapeutic equivalent generic version of Cubicin® for Injection, approved by the U.S.
- Business Wire•2 months ago
Dr. Reddy's Laboratories Announces the Launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g Pump Actuation) in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel® 1.62%, approved by the U.S.
- Simply Wall St.•2 months ago
Is Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) CEO Overpaid Relative To Its Peers?
Gunupati Prasad became the CEO of Dr. Reddy's Laboratories Limited (NSE:DRREDDY) in 2001. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Then...
- Business Wire•2 months ago
Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019
Earnings call slated for May 17, 6:00 PM IST / 8:30 AM EDT
- Business Wire•2 months ago
Dr. Reddy's Laboratories Announces Acquisition of ANDA Portfolio
Dr. Reddy’s Laboratories Ltd. announced today that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications in the U.S.
- Business Wire•3 months ago
Promius Pharma, LLC. (a Wholly Owned Subsidiary of Dr. Reddy’s Laboratories Ltd.) Announces the Sale and Assignment of the US Rights for Its Marketed Dermatology Brands to Encore Dermatology
Dr. Reddy’s Laboratories Limited , through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for SERNIVO® Spray, 0.05% and assignment of its rights to market and distribute, PROMISEB® Topical Cream and TRIANEX® 0.05% in the United States, to Encore Dermatology.
- Business Wire•3 months ago
Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. , along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Cialis Tablets in the United States market, approved by the U.S.
- Simply Wall St.•3 months ago
Taking A Look At Dr. Reddy’s Laboratories Limited’s (NSE:DRREDDY) ROE
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use ReturnRead More...
- Business Wire•4 months ago
Dr. Reddy's Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation
Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today the re-launch of its Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone® sublingual film, in the United States market.
- Simply Wall St.•5 months ago
Who Has Been Buying Dr. Reddy’s Laboratories Limited (NSE:DRREDDY) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up sharesRead More...
- Business Wire•5 months ago
Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling
Dr. Reddy’s Laboratories Ltd. announced that its wholly owned subsidiary, Dr Reddy’s Laboratories, Inc, is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetam in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL single-dose infusion bags to the hospital level in U.S.A.
- Business Wire•5 months ago
Dr. Reddy's Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America
Dr. Reddy’s Laboratories Ltd. , along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the appointment of Marc Kikuchi as Chief Executive Officer, North America Generics.
- Business Wire•5 months ago
Dr. Reddy’s Q3 FY19 Financial Results
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter ended December 31, 2018 under International Financial Reporting Standards .
- Reuters•5 months ago
Dr. Reddy's third-quarter profit surges on strong growth in emerging markets
(Reuters) - Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 65.3 percent surge in quarterly profit on Friday, handily beating market expectations, helped by strong growth in emerging markets. ...
